ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2252

Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results from a Post Hoc Analysis of the FINCH 4 Study
Abstract Number: 1104

Long-term Follow-up of Patients with Positive Cryofibrinogen Test During the COVID-19 Era
Abstract Number: 1246

Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies
Abstract Number: 0458

Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Abstract Number: 2501

Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency
Abstract Number: 2482

Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies
Abstract Number: 1094

Longitudinal Analysis of Serum Urate in Prediabetic Phase
Abstract Number: 0238

Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals
Abstract Number: 2357

Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies
Abstract Number: 2490

Longitudinal Kidney Function Trajectories in Patients Enrolled in the Plasma Exchange and Glucocorticoids in ANCA-Associated Vasculitis Trial
Abstract Number: 0270

Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Abstract Number: 1227

Longitudinal Patterns of Fibromyalgia Phenotypes in Patients with Systemic Lupus Erythematosus
Abstract Number: 1656

Loss of Nr4a1 Expression Protects Cartilage During Post-traumatic Osteoarthritis
Abstract Number: 2184

Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE
Abstract Number: 1396

Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].